NeuroPace (NASDAQ:NPCE) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

NeuroPace (NASDAQ:NPCE) posted its quarterly earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07, Zacks reports. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

NeuroPace Stock Up 0.9 %

NASDAQ NPCE traded up $0.11 during trading hours on Tuesday, hitting $11.92. The company had a trading volume of 245,547 shares, compared to its average volume of 119,388. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace has a fifty-two week low of $5.45 and a fifty-two week high of $16.34. The company has a market capitalization of $355.79 million, a price-to-earnings ratio of -11.92 and a beta of 2.05. The firm’s 50 day moving average is $12.70 and its 200 day moving average is $9.71.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the business’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Martha Morrell sold 3,200 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the sale, the insider now owns 87,062 shares of the company’s stock, valued at $1,306,800.62. This represents a 3.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 5,352,479 shares of company stock worth $50,670,217. 22.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price on the stock. Wells Fargo & Company upped their price target on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, January 30th. Finally, JPMorgan Chase & Co. lifted their price objective on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $14.80.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.